Suman Chandra Nath

Suman Chandra Nath

Auto-generated profile, based on publicly available information

Suman Chandra Nath

Cell Therapy Process Department, Lonza Inc., Houston, TX 77047, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2016 in Bioprocess and Biosystems Engineering
Verified
Journal Article
Closed access
PDF file
SNSuman Chandra Nath
Suman Chandra Nath
ENEiji Nagamori
Eiji Nagamori
MHMasanobu Horie
Masanobu Horie
MKMasahiro KINO-OKA
Masahiro KINO-OKA

Verified
Journal Article
Open access
PDF file
SNSuman C. Nath
Suman C. Nath
LMLaura Menendez
Laura Menendez
INInbar Friedrich Ben Nun
Inbar Friedrich Ben Nun
Various factors are known to contribute to the diversity of human induced pluripotent stem cells (hiPSCs). Among these are the donor’s genetic background and family history, the somatic cell source, the iPSC reprogramming method, and the culture system of choice. Moreover, variability is seen even in iPSC clones, generated in a single reprogramming event, where the donor, somatic cell type, and reprogramming platform are the same. The diversity seen in iPSC lines often translates to epigenetic differences, as well as to differences in the expansion rate, iPSC line culture robustness, and their ability to differentiate into specific cell types. As such, the diversity of iPSCs presents a hurdle to standardizing iPSC-based cell therapy manufacturing. In this review, we will expand on the various factors that impact iPSC diversity and the strategies and tools that could be taken by the industry to overcome the differences amongst various iPSC lines, therefore enabling robust and reproducible iPSC-based cell therapy manufacturing processes.

1 October 2017 in Journal of Bioscience and Bioengineering
Verified
Journal Article
Closed access
SNSuman C. Nath
Suman C. Nath
MHMasanobu Horie
Masanobu Horie
ENEiji Nagamori
Eiji Nagamori
MKMasahiro KINO-OKA
Masahiro KINO-OKA

1 December 2019 in Stem Cell Research
Verified
Journal Article
Open access
LGLijie Gao
Lijie Gao
SNSuman C. Nath
Suman C. Nath
XJXiyao Jiao
Xiyao Jiao
RZRongyan Zhou
Rongyan Zhou
SNSandra Nishikawa
Sandra Nishikawa
DRDerrick E. Rancourt
Derrick E. Rancourt
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) are prone to anoikis after single cell dissociation. The small molecule, Y-27632 is known to increase survival of hESCs and hiPSCs by inhibiting the Rho-associated protein kinase (ROCK). However, the underlying mechanisms are still unclear. Here, we thoroughly screened small molecules to investigate the adhesion and survival of hESCs in adherent culture. Y-27632 provided higher adhesion and survival of hESCs by increased cell migration and preventing cell blebbing in single dissociated cells. The combination of Matrigel with poly-d-lysine increased the attachment and survival of dissociated cells via actin filament and microtubule spreading in Y-27632-treated cells. Although Y-27632 prevented apoptosis by suppressing actin filament contraction, microtubule bundling, and blebbing, prolonged Y-27632 treatment presented a different morphology in the attached growing hESC colony. It induced apoptosis of cells by promoting cytoplasmic spread, E-cadherin structural change, and increased detachment. It also induced actin cytoskeleton disruption, combined with microtubule and intermediate filament elongation. For optimal hPSC culture, our research suggests that Y-27632 should be removed shortly after passaging.